dc.contributor.author | Garcia-Partida, Jose Antonio | |
dc.contributor.author | Torres-Sanchez, Sonia | |
dc.contributor.author | MacDowell, Karina | |
dc.contributor.author | Fernández-Ponce, Maria Teresa | |
dc.contributor.author | Casas, Lourdes | |
dc.contributor.author | Mantell, Casimiro | |
dc.contributor.author | Soto-Montenegro, María Luisa | |
dc.contributor.author | Romero-Miguel, Diego | |
dc.contributor.author | Lamanna-Rama, Nicolás | |
dc.contributor.author | Leza, Juan Carlos | |
dc.contributor.author | Desco, Manuel | |
dc.contributor.author | Berrocoso, Esther | |
dc.date.accessioned | 2023-04-11T12:58:24Z | |
dc.date.available | 2023-04-11T12:58:24Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Front Pharmacol. 2022 Jul 26;13:886514 | es_ES |
dc.identifier.issn | 1663-9812 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/15757 | |
dc.description.abstract | There is evidence that in schizophrenia, imbalances in inflammatory and oxidative processes occur during pregnancy and in the early postnatal period, generating interest in the potential therapeutic efficacy of anti-inflammatory and antioxidant compounds. Mangiferin is a polyphenolic compound abundant in the leaves of Mangifera indica L. that has robust antioxidant and anti-inflammatory properties, making it a potential candidate for preventive or co-adjuvant therapy in schizophrenia. Hence, this study set-out to evaluate the effect of mango leaf extract (MLE) in a model of schizophrenia based on maternal immune activation, in which Poly I:C (4 mg/kg) is administered intravenously to pregnant rats. Young adult (postnatal day 60-70) or adolescent (postnatal day 35-49) male offspring received MLE (50 mg/kg of mangiferin) daily, and the effects of MLE in adolescence were compared to those of risperidone, assessing behavior, brain magnetic resonance imaging (MRI), and oxidative/inflammatory and antioxidant mediators in the adult offspring. MLE treatment in adulthood reversed the deficit in prepulse inhibition (PPI) but it failed to attenuate the sensitivity to amphetamine and the deficit in novel object recognition (NOR) induced. By contrast, adolescent MLE treatment prevented the sensorimotor gating deficit in the PPI test, producing an effect similar to that of risperidone. This MLE treatment also produced a reduction in grooming behavior, but it had no effect on anxiety or novel object recognition memory. MRI studies revealed that adolescent MLE administration partially counteracted the cortical shrinkage, and cerebellum and ventricle enlargement. In addition, MLE administration in adolescence reduced iNOS mediated inflammatory activation and it promoted the expression of biomarkers of compensatory antioxidant activity in the prefrontal cortex and hippocampus, as witnessed through the reduction of Keap1 and the accumulation of NRF2 and HO1. Together, these findings suggest that MLE might be an alternative therapeutic or preventive add-on strategy to improve the clinical expression of schizophrenia in adulthood, while also modifying the time course of this disease at earlier stages in populations at high-risk. | es_ES |
dc.description.sponsorship | EB, JAG-P and ST-S work was supported by the “Fondo
Europeo de Desarrollo Regional” (FEDER)-UE “A way to build
Europe” from the “Ministerio de Economía y Competitividad”
(RTI2018-099778-B-I00); from the “Plan Nacional sobre Drogas,
Ministerio de Sanidad, Consumo y Bienestar Social” (2019I041);
from the “Ministerio de Salud-Instituto de Salud Carlos III”
(PI18/01691); from the “Programa Operativo de Andalucía
FEDER, Iniciativa Territorial Integrada ITI 2014-2020
Consejería Salud y Familias, Junta de Andalucía” (PI-0080-
2017, PI-0009-2017), “Consejería de Salud y Familias, Junta
de Andalucía” (PI-0134-2018 and PEMP-0008-2020); from the
“Consejería de Transformación Económica, Industria,
Conocimiento y Universidad, Junta de Andalucía” (P20_00958
and CTS-510); from the CEIMAR (CEIJ-003); from the
“Instituto de Investigación e Innovación en Ciencias
Biomédicas de Cádiz-INiBICA” (LI19/06IN-CO22; IN-C09);
from the “CIBERSAM”: CIBER-Consorcio Centro de
Investigación Biomédica en Red- (CB07/09/0033), Instituto de
Salud Carlos III, Ministerio de Ciencia e Innovación and from the
European Union’s Horizon 2020 research and innovation
programme under the Marie Sklodowska-Curie grant
agreement No 955684. CM, LC and MTF-P were supported
by the Spanish Ministry of Science and Technology (PID2020-
116229RB-I00) and European Regional Development Fund
(ERDF). KM and JCL were supported by the “MICINN”
(PID2019-109033RB-I00) and the “CIBERSAM”: CIBERConsorcio Centro de Investigación Biomédica en Red- (CB07/
09/0026), Instituto de Salud Carlos III, Ministerio de Ciencia e
Innovación. MLS-M was supported by the “Ministerio de
Ciencia, Innovación, Instituto de Salud Carlos III” (PI17/
01766, BA21/00030), co-financed by European Regional
Development Fund (ERDF), “A way to make Europe”; from the “CIBERSAM”: CIBERConsorcio Centro de Investigación
Biomédica en Red- (CB07/09/0031), Instituto de Salud Carlos
III, Ministerio de Ciencia e Innovación; from the “Delegación del
Gobierno para el Plan Nacional sobre Drogas” (2017/085); from
the “Fundación Mapfre” and “Fundación Alicia Koplowitz.” MD
work was supported by the “Ministerio de Ciencia e In review 18/
28 Innovación” (MCIN) and “Instituto de Salud Carlos III”
(ISCIII) (PT20/00044); from the “CIBERSAM” CIBERConsorcio Centro de Investigación Biomédica en Red-(CB07/
09/0031). The CNIC is supported by the ISCIII, the MCIN and
the Pro CNIC Foundation, and is a Severo Ochoa Center of
Excellence (SEV-2015-0505). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | The effects of mango leaf extract during adolescence and adulthood in a rat model of schizophrenia. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 35959428 | es_ES |
dc.format.volume | 13 | es_ES |
dc.format.page | 886514 | es_ES |
dc.identifier.doi | 10.3389/fphar.2022.886514 | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | es_ES |
dc.contributor.funder | Plan Nacional de Drogas (España) | es_ES |
dc.contributor.funder | Ministerio de Salud (España) | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Regional Government of Andalusia (España) | es_ES |
dc.contributor.funder | Centro de Investigación Biomédica en Red - CIBERSAM (Salud Mental) | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
dc.contributor.funder | Unión Europea. Comisión Europea. H2020 | es_ES |
dc.contributor.funder | Marie Curie | es_ES |
dc.contributor.funder | Ministerio de Ciencia y Tecnología (España) | es_ES |
dc.contributor.funder | Fundación Mapfre | es_ES |
dc.contributor.funder | Fundación Alicia Koplowitz | es_ES |
dc.contributor.funder | Fundación ProCNIC | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | 10.3389/fphar.2022.886514 | es_ES |
dc.identifier.journal | Frontiers in pharmacology | es_ES |
dc.repisalud.orgCNIC | CNIC::Unidades técnicas::Imagen Avanzada | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/ERC/955684 | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RTI2018-099778-B-I00 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/2019I041 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI18/01691 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI-0080-2017 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI-0009-2017 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI-0134-2018 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PEMP-0008-2020 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/P20-00958 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CTS-510 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CEIJ-003 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/LI19/06IN-CO22 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/IN-C09 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CB07/09/0033 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PID2020-116229RB-I00 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI17/01766 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/BA21/00030 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PT20/00044 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/SEV-2015-0505 | es_ES |